|
characteristic
|
No. of patients
|
%
|
|---|
|
Age(yrs)
| | |
|
Median
|
54.0
| |
|
Range
|
26.0-79.0
| |
|
Sex
| | |
|
Male
|
49
|
61.3
|
|
Female
|
31
|
38.7
|
|
ECOG performance status
| | |
|
0
|
36
|
45.0
|
|
1
|
42
|
52.5
|
|
2
|
2
|
2.5
|
|
Primary sites
| | |
|
Cardia
|
21
|
26.3
|
|
Body
|
18
|
22.5
|
|
Antrum/pylorus
|
41
|
51.2
|
|
Metastatic sites
| | |
|
Liver
|
26
|
32.5
|
|
Lung
|
21
|
26.3
|
|
Peritoneum
|
19
|
23.8
|
|
Others
|
14
|
17.4
|
|
Pathologic differentiation N0
| | |
|
G1
|
2
|
2.5
|
|
G2
|
26
|
32.5
|
|
G3
|
52
|
65.0
|
|
Treatment Response (1st line)
| | |
|
CR
|
2
|
2.5
|
|
PR
|
36
|
45.0
|
|
SD
|
24
|
30.0
|
|
PD
|
18
|
22.5
|
|
2nd-line chemotherary regimen
| | |
|
BSC
|
57
|
71.3
|
|
FOLFIRI
|
6
|
7.5
|
|
XELIRI
|
8
|
10.0
|
|
DX
|
6
|
7.5
|
|
TP
|
3
|
3.7
|
- CR, complete response; PR, partial response; SD, stable disease; PD, progression disease;
- BSC, best supportive care; FOLFIRI, 5-fluracil plus leucovorin plus irinotecan; XELIRI, capecitabine plus irinotecan; DX, docitaxel plus capecitabine; TP, paclitaxel plus cisplatin.
